Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 10, 2023

Primary Completion Date

July 17, 2024

Study Completion Date

August 8, 2024

Conditions
Non-cystic Fibrosis BronchiectasisPseudomonas AeruginosaLung Infection
Interventions
BIOLOGICAL

AP-PA02

Bacteriophage administered via inhalation

OTHER

Placebo

Inactive Placebo administered via inhalation

Trial Locations (23)

10595

New York Medical College, Hawthorne

19104

University of Pennslyvania, Philadelphia

20007

Georgetown University Hospital / Pulmonary Critical Care and Sleep Medicine, Washington D.C.

21224

Johns Hopkins University School of Medicine, Baltimore

23298

Virginia Commonwealth University (VCU), Richmond

29425

Medical University of South Carolina, Charleston

32224

Mayo Clinic/Pulmonary, Critical Care, and Sleep Medicine, Jacksonville

33024

TecTum Medical Research, Inc., Hollywood

33146

University of Miami, Miami

33907

Southwest General Healthcare Center, Fort Myers

36608

Velocity Clinical Research, Mobile

37203

Vanderbilt University Medical Center, Nashville

44106

University Hospitals of Cleveland Medical Center, Cleveland

45267

University of Cincinnati - College of Medicine, Cincinnati

55905

Mayo Clinic, Rochester

66160

The University of Kansas Medical Center / Dept of Medicine, Kansas City

75708

University of Texas Health Science Center at Tyler, Tyler

83702

St. Lukes Hospital, Boise

90048

Southern California Institute for Respiratory Diseases Cedars-Sinai West Tower, Los Angeles

97239

Oregon Health & Science University, Portland

98195

University of Washington Medical Center, Seattle

06030

UCONN Health, Farmington

08901

Rutgers Robert Wood Johnson Medical School, New Brunswick

Sponsors
All Listed Sponsors
lead

Armata Pharmaceuticals, Inc.

INDUSTRY